Is It Too Late To Consider Capital Power (TSX:CPX) After Strong Multi‑Year Gains?

Wondering if Capital Power at around $64.99 is still offering fair value or starting to look stretched? This article walks ...

Assessing Capital Power (TSX:CPX) Valuation After Recent Share Price Moves And Undervaluation Debate

Why Capital Power is on investors’ radar today Capital Power (TSX:CPX) has drawn fresh interest after recent share price ...
ascopubs.org

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid ...

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials This phase III, open-label study ...
The American Journal of Managed Care

CPX-351 Effective in AML, Possibly With Reduced Cardiotoxicity vs Standard Anthracyclines

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity. In a study of ...